Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Other

Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO(TM) in Canada from Knight

By The Northwire Desk — AI Analysis Nov 10, 2025 · 16:30 PRN · 8.37 PROFOUND MEDICAL CORP.
PRN · Price

Executive Summary

  • Profound Medical Corp. has regained exclusive Canadian distribution rights for its TULSA‑PRO® prostate therapy system from Knight Therapeutics.
  • The transaction involved a one‑time cash payment of CDN $90,000 (US $64,000) and a 5% royalty on Canadian net sales for the next 15 years.
  • Profound plans to expand the TULSA‑PRO business in Canada through its own sales team, additional clinical sites, and future reimbursement submissions following upcoming trial results.

Key Details

  • Agreement Terms: One‑time cash consideration of CDN $90,000; ongoing royalty of 5% on Canadian net sales for a 15‑year term.
  • Previous Arrangement: Knight Therapeutics had been the exclusive distributor since April 2015.
  • Commercial Strategy: Profound will deploy its North American direct sales force and pursue additional Canadian sites (currently only Sunnybrook Health Sciences Centre) using an interim concierge service model.
  • Regulatory Status: TULSA‑PRO is CE‑marked, Health Canada approved, and FDA 510(k) cleared.
  • Clinical Context: More than 100 procedures have been performed at Sunnybrook; results from the Level I CAPTAIN trial (comparing TULSA to robotic radical prostatectomy) are expected in 2026 and will support provincial reimbursement applications.
  • Future Opportunity: If provincial coverage is obtained, Profound anticipates broader adoption across Canadian hospitals.

Notable Quotes

“Knight has been a strong supporter of Profound… The launch of TULSA‑PRO in Canada … will be served best by Profound’s North American integrated commercial and clinical teams.” – Samira Sakhia, President & CEO, Knight Therapeutics

“Toronto’s renowned Sunnybrook Health Sciences Centre … has already performed more than 100 TULSA Procedures… we plan to use trial results to support applications for provincial coverage.” – Arun Menawat, CEO & Chairman, Profound Medical Corp.

Read the original news release →

More from PROFOUND MEDICAL CORP.

May 15, 2026 · 06:30

Profound Medical Corp.

Other May 14, 2026 · 07:00

TULSA-PRO's Conference Glow Hides a Long Road to Profitability

Other May 07, 2026 · 16:05

Humana coverage and surging procedure volumes push TULSA-PRO toward standard of care, but path to profitability still requires execution.

Earnings Mar 27, 2026 · 15:15

Profound talks up Tulsa procedure milestone in Texas

Production / Operations Mar 27, 2026 · 07:45

Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure(TM) Milestone

Other Mar 13, 2026 · 10:30

CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure(TM) to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence

Other